Engraftment, graft-vs-host disease (GVHD), and survival after CD8+T cell depleted allogeneic peripheral blood stem cell transplantation (PBSCT).

被引：0
|
作者：
Soiffer, RJ [1 ]
Alyea, EP [1 ]
Kim, H [1 ]
Parikh, B [1 ]
Ho, V [1 ]
Hochberg, E [1 ]
Levin, J [1 ]
Fisher, DC [1 ]
Lee, SJ [1 ]
Antin, JH [1 ]
机构：
[1] Dana Farber Canc Inst, Div Med Oncol, Boston, MA 02115 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1619
引用
收藏
页码：418A / 418A
页数：1
相关论文
共 50 条
  • [1] Chronic graft-vs-host disease (GVHD) after allogeneic marrow or blood stem cell transplantation
    Anderlini, P
    Przepiorka, D
    Khouri, I
    vanBesien, K
    Mehra, R
    Giralt, S
    Gajewski, J
    Cleary, K
    Champlin, R
    Andersson, B
    Korbling, M
    BLOOD, 1995, 86 (10) : 421 - 421
  • [2] Is cyclosporine (CSA) necessary to prevent graft-versus-host-disease (GVHD) after T cell depleted peripheral blood stem cell transplantation (PBSCT)?
    Solomon, SR
    Nakamura, R
    Read, EJ
    Leitman, SF
    Childs, RW
    Dunbar, CE
    Young, NS
    Barrett, AJ
    BLOOD, 2001, 98 (11) : 416A - 416A
  • [3] Allogeneic peripheral blood stem cell transplantation (PBSCT) for hematological malignancy with tacrolimus monotherapy as prophylaxis for graft-vs-host disease (GVRD).
    Ball, ED
    deMagalhaesSilverman, M
    Rybka, WR
    Kiss, JC
    Hammert, L
    Simpson, J
    Wilson, J
    BLOOD, 1997, 90 (10) : 4395 - 4395
  • [4] Tacrolimus vs cyclosporine for prevention of acute graft-vs-host disease (GVHD) after allogeneic blood stem cell transplantation.
    Przepiorka, D
    Ippoliti, C
    Khouri, I
    Anderlini, P
    Stein, L
    vanBesien, K
    Mehra, R
    Giralt, S
    Gajewski, J
    Fritsche, H
    Deisseroth, AB
    Cleary, K
    Champlin, R
    Andersson, B
    Korbling, M
    BLOOD, 1995, 86 (10) : 1568 - 1568
  • [5] CD8+T cell depleted allogeneic peripheral stem cell transplantation (PBSCT) using antibody coated high density microparticles
    Soiffer, R
    Alyea, E
    Parikh, B
    Lee, S
    Antin, J
    BONE MARROW TRANSPLANTATION, 2002, 29 : S200 - S200
  • [6] High incidence of peri-engraftment fever and rash in patients after CD8 T cell depleted allogeneic myeloablative peripheral blood stem cell transplantation (PBSCT).
    Ho, VT
    Sackstein, R
    Cutler, C
    Hochberg, E
    Alyea, EP
    Lee, SJ
    Antin, JH
    Soiffer, JS
    BLOOD, 2003, 102 (11) : 710A - 710A
  • [7] Donor T lymphocyte engraftment is facilitated by higher CD34 cell doses in T cell depleted myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT).
    Battiwalla, M
    Kurlander, R
    Solomon, SR
    Wehrlen, L
    Greene, A
    Barrett, AJ
    BLOOD, 2003, 102 (11) : 709A - 709A
  • [8] Allogeneic blood stem cell transplantation: Graft vs host disease (GVHD) and graft vs leukemia (GVL) effect
    Korbling, M
    BONE MARROW TRANSPLANTATION, 1998, 22 : S6 - S6
  • [9] CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation
    Mohty, M
    Bagattini, S
    Chabannon, C
    Faucher, C
    Bardou, VJ
    Bilger, K
    Vey, N
    Gaugler, B
    Stoppa, AM
    Coso, D
    Ladaique, P
    Olive, D
    Viens, P
    Blaise, D
    EXPERIMENTAL HEMATOLOGY, 2004, 32 (11) : 1097 - 1102
  • [10] Microdose methotrexate vs methylprednisolone in combination with tacrolimus for prevention of acute graft-vs-host disease (GVHD) after allogeneic blood stem cell transplantation.
    Przepiorka, D
    Ippoliti, C
    Khouri, I
    Anderlini, P
    LeBherz, D
    vanBesien, K
    Ueno, N
    Mehra, R
    Giralt, S
    Gajewski, J
    Fritsche, H
    Cleary, K
    Claxton, D
    Champlin, R
    Andersson, B
    Korbling, M
    BLOOD, 1996, 88 (10) : 1659 - 1659
12345